Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma

Anticancer Research

Volumn 27, Issue 3 A, 2007, Pages 1277-1284

  Murphy, L ^a   Clynes, M ^a   Keenan, Joanne ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Differential protein expression; Drug resistance; Lung cancer; Mitoxantrone

Indexed keywords

MITOXANTRONE;

APOPTOSIS; CELL DIFFERENTIATION; COMPUTER PROGRAM; CONFERENCE PAPER; DRUG RESISTANCE; HUMAN; HUMAN CELL; LUNG CARCINOMA; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ACRIDINES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MITOXANTRONE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TETRAHYDROISOQUINOLINES;

EID: 34249320200     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Longley D and Johnston P: Molecular mechanisms of drug resistance. J Pathol 205: 275-292, 2005.
2. Modok S, Mellor HR and Callaghan R: Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharm 6: 350-354, 2006.
3. Doyle LA and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358, 2003.
4. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670, 1998.
5. Chen Gomez SP, McCarley D and Mainwaring MG: Topotecan-induced topoisomerase II alpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Cancer Chemother Pharmacol 49: 347-355, 2002.
6. Diestra JE, Scheffer GL, Catala II, Maliepaard M, Schellens JH, Scheper RJ, Germa-Lluch JR and Izquierdo MA: Lung-resistance related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. J Pathol 198: 213-219, 2002.
7. Liang Y, O'Driscoll L, McDonnell S, Doolan P, Oglesby I, Duffy K, O'Connor R and Clynes M: Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anti cancer drugs. Int J Cancer 111: 484-493, 2004.
8. Diah SK, Smitherman PK, Aldridge J, Volk EL, Schneider E, Townsend AJ and Morrow CS: Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res 15: 5461-5467, 2001.
9. Law E, Gilvarry U, Lynch V, Gregory G, Grant G and Clynes M: Cytogenetic comparison of two poorly-differentiated human lung squamous cell carcinoma lines. Cancer Genet Cytogenet 59: 111-118, 1992.
10. Laemmli E and Favre M: Mutation of the head of bacteriophage T4. J Mol Biol 80: 575-579, 1973.
11. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
12. Keenan J, Liang Y and Clynes M: Two-deoxyglucose as an anti-metabolite in human carcinoma cell line RPMI-2650 and drug-resistant variants. Anticancer Res 24: 433-440, 2004.
13. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci 22: 15665-15670, 1998.
14. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JMG, Kardia SLR, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SH and Beer DG: Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 8: 2298-2305, 2002.
15. Nakanishi T, Karo JE, Tan M, Doyle LA, Peters T, Yang W, Wei D and Ross DD: Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukaemia patients. Clin Cancer Res 9: 3320-3328, 2005.
16. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D and Lage H: Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis 20: 2961-2969, 1999.
17. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D and Lage H: Increased expression of epidermal fatty acid binding protein, cofilin and 14-3-3-σ (stratifin) detected by two-dimensional electrophoresis, mass spectrometry and microsequencing in drug-resistant human adenocarcinoma of the pancreas. Electrophoresis 20: 2652-2660, 1999.
18. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D and Lage H: Increased expression of annexin 1 and thioredoxin detected by two-dimensional gel electrophoresis in drug-resistant human stomach cancer cells. J Biochem Biophys Methods 18: 105-116, 1998.
19. Fu Z and Fenselau C: Proteomic evidence for roles for nuleolin and poly[ADP-ribosyl] transferase in drug resistance. J Proteome Res 4: 1583-1591, 2005.
20. An Y, Fu Z, Gutierrez P and Fenselau C: Solution isoelectric focusing for peptide analysis: comparative investigations of an insoluble nuclear protein fraction. J Proteome Res 4: 2126-2132, 2005.
21. Shah Braverman R and Prasad GL: Suppression of neoplastic transformation and regulation of cytoskeleton by tropomyosins. Somat Cell Mol Genet 24: 273-280, 1998.
22. Yoo BC, Ku JL, Hong SH, Shin YK, Park SY, Kim HK and Park JG: Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 108: 532-539, 2004.
23. Varga AE, Stourman NV, Zheng Q, Safina AF, Quan L, Li X, Sossey-Alaoui K and Bakin AV: Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta. Oncogene 24: 5043-5052, 2005.
24. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM and Schmidt AM: Blockage of RAGE-amphoterin signalling suppresses tumour growth and metastasis. Nature 405: 354-360, 2000.
25. Tsai HW, Chow NH, Lin CP, Chan SH, Chou CY and Ho CL: The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Human Pathology 37: 198-204, 2006.
26. Ahn MJ, Lee KL, Yoo YD, Lee YS, Choi YH, Lee YY and Kim IS: The differential gene expression profiles between sensitive and resistant gastric cancer cells to 5-fluorouracil and cisplatin by cDNA microarray. Proc Am Soc Clin Oncol 22: 1146, 2003.
27. Liu Y, Liu H, Han B and Zhang JT: Identification of 14-3-3σ as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66: 3248-3255, 2006.
28. Chen S, Gomez SP, McCarley D and Mainwaring MG: Topotecan-induced topoisomerase II α expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Cancer Chemother Pharmacol 49: 347-355, 2002.
29. Zhu B, Fukada B, Zhu H and Kyprianou N: Prohibitin and Cofilin Are Intracellular Effectors of Transforming Growth Factor β Signaling in Human Prostate Cancer Cells. Cancer Res 66: 8640-8647, 2006.
30. Narayanan NK, Narayanan BA and Nixon DW: Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluation. Cancer Detection and Prevention 28: 443-452, 2004.